131 related articles for article (PubMed ID: 23503552)
1. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
Takaki M; Ujike H
Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
[TBL] [Abstract][Full Text] [Related]
2. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
[TBL] [Abstract][Full Text] [Related]
3. Blonanserin ameliorates social deficit through dopamine-D
Takeuchi S; Hida H; Uchida M; Naruse R; Yoshimi A; Kitagaki S; Ozaki N; Noda Y
Neurochem Int; 2019 Sep; 128():127-134. PubMed ID: 30998952
[TBL] [Abstract][Full Text] [Related]
4. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
5. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
[TBL] [Abstract][Full Text] [Related]
6. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Etievant A; Bétry C; Arnt J; Haddjeri N
Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
[TBL] [Abstract][Full Text] [Related]
7. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
8. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
Huang M; Kwon S; Oyamada Y; Rajagopal L; Miyauchi M; Meltzer HY
Pharmacol Biochem Behav; 2015 Nov; 138():49-57. PubMed ID: 26383990
[TBL] [Abstract][Full Text] [Related]
10. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity.
Suzuki H; Gen K
Hum Psychopharmacol; 2010; 25(4):342-6. PubMed ID: 20521325
[TBL] [Abstract][Full Text] [Related]
11. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
Gründer G
Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
[TBL] [Abstract][Full Text] [Related]
12. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.
Kim SW; Shin IS; Kim JM; Youn T; Yang SJ; Hwang MY; Yoon JS
Clin Neuropharmacol; 2009; 32(4):224-6. PubMed ID: 19644229
[TBL] [Abstract][Full Text] [Related]
13. The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets.
Kotani M; Enomoto T; Murai T; Nakako T; Iwamura Y; Kiyoshi A; Matsumoto K; Matsumoto A; Ikejiri M; Nakayama T; Ogi Y; Ikeda K
Behav Brain Res; 2016 May; 305():212-7. PubMed ID: 26970575
[TBL] [Abstract][Full Text] [Related]
14. [Functional role of dopamine D3 receptor in schizophrenia].
Semba J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
[TBL] [Abstract][Full Text] [Related]
15. Three cases of schizophrenia showing improvement after switching to blonanserin.
Kurotaki N; Nobata H; Nonaka S; Nishihara K; Ozawa H
Psychiatry Clin Neurosci; 2011 Jun; 65(4):396-7. PubMed ID: 21682816
[No Abstract] [Full Text] [Related]
16. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
18. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
19. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
20. Blonanserin in the treatment of delirium.
Kato K; Yamada K; Maehara M; Akama F; Kimoto K; Saito M; Yano H; Ichimura A; Matsumoto H
Psychiatry Clin Neurosci; 2011 Jun; 65(4):389-91. PubMed ID: 21569175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]